VPT:CC - Enhanced Design Breakthrough Makes Ventripoint's VMS+ Even Simpler to Use
(TheNewswire)
***Faster, User Friendly Cardio AI Imaging Product forCommercial Roll Out***
Toronto, Ont. — TheNewswire --- March 04, 2024 — VentripointDiagnostics Ltd. ("Ventripoint" or the "Company"),(TSXV:VPT ) ; ( OTC:VPTDF) releaseda significant upgrade to the design and function of its whole-heartanalysis system (VMS+3.2), which accelerates imaging, analysis andease of use at the point of care.
The new design allows immediate calibration by technicians withexisting ultrasound equipment to more quickly generate 2D ultrasoundimages, which the VMS+3.2 turns into a high-definition 3D heart model.The upgraded system also includes an improved 3D visualization tool,which speeds up and facilitates the analysis of 3D ultrasound exams.
VMS+3.2 release improves the ease-of-use of 2D and 3D echocardiogramprocedures for sonographers, cardiologists and caregivers, assuringseamless integration of Ventripoint technology into patient-careworkflow and standard of care. In a busy echocardiography unit,reducing the time for a procedure without compromising the quality ofthe results is a constant challenge and the VMS+3.2 will beappreciated for these innovations.
“We are constantly improving the design of our system, to generateefficiencies and better outcomes,” said Ventripoint’s Interim CEO,Hugh MacNaught. “This is a best-in-class diagnostic tool that allowsenhanced echocardiograms of infants and adults to be available fasterand at less cost than a cardiac MRI, with equivalent structural andfunctional results.”
The new design removes the magnet from the probe-tracking system andso it is now immune to environments where magnetic fields are presentand is no longer a concern for implanted patient medical devices, suchas pacemakers and other cardiac devices, where magnets can bedisruptive. The Company intends to submit to regulatory agencies forthe removal of this limitation on the VMS+ system.
Ventripoint’s technology is now being used in leading hospitals inEurope, the UK, Canada, China and the United States as an alternativeto traditional MRI heart scans. These users will be offered theVMS+3.2 upgrade for a fee and future sales will be of the VMS+3.2version. The Company is now focused on expanding the user base inhospitals and clinics worldwide.
The Company has a world-class board of clinical advisors who continueto provide ideas for design improvements, which are ongoing. Thecompany expects to announce additional enhancements in 2024, whichwill require regulatory approvals and enable VMS+ to be used with awider range of patients. It is important to note that these futureupgrades are software improvements, which can be seamlessly integratedinto existing and new VMS+ units.
For further information, pleasecontact:
Jonathan Robinson CFA
(416) 669-1001
Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.
About Ventripoint DiagnosticsLtd.
Ventripoint has become an industry leader in the application of AI(Artificial Intelligence) to echocardiography. Ventripoint's VMSproducts are powered by its proprietary KBR technology, which is theresult of a decade of development and provides accurate volumetriccardiac measurements equivalent to MRI. This affordable, gold-standardalternative allows cardiologists greater confidence in the managementof their patients. Providing better care to patients serves as aspringboard and basic standard for all Ventripoint's products thatguide our future developments. In addition, VMS+ is versatile and canbe used with all ultrasound systems from any vendor supported byregulatory market approvals in the U.S., Europe, and Canada.
Forward Looking Statements
This news release contains forward-looking statements andforward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' and similarexpressions are intended to identify forward-looking information orstatements. The forward-looking statements and information are basedon certain key expectations and assumptions made by the Company.Although the Company believes that the expectations and assumptions onwhich such forward-looking statements and information are based arereasonable, undue reliance should not be placed on the forward-lookingstatements and information because the Company can give no assurancethat they will prove to be correct.
Since forward-looking statements and information address future eventsand conditions, by their very nature they involve inherent risks anduncertainties. Actual results could differ materially from thosecurrently anticipated due to several factors and risks. Factors whichcould materially affect such forward-looking information are describedin the risk factors in the Company's most recent annual management'sdiscussion and analysis that is available on the Company's profile onSEDAR at www.sedar.com. Readers are cautioned that theforegoing list of factors is not exhaustive. The forward-lookingstatements included in this news release are expressly qualified bythis cautionary statement. The forward-looking statements andinformation contained in this news release are made as of the datehereof and the Company undertakes no obligation to update publicly orrevise any forward-looking statements or information, whether becauseof new information, future events or otherwise, unless so required byapplicable securities laws.
Copyright (c) 2024 TheNewswire - All rights reserved.